Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Caregiving

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Alzheimer's disease (AD) is the most common form of neurodegenerative disorder with dementia, accounting for approximately 70% of the all cases. Currently, 5.8 million people in the U.S. are living with AD and by 2050 this number is expected to double resulting in a significant socio-economic burden. Despite intensive research, the exact mechanisms that trigger AD are still not known and at the present there is no cure for it. In recent years, many signaling pathways associated with AD neuropathology have been explored as possible candidate targets for the treatment of this condition including glycogen synthase kinase-3β (GSK3-β). GSK3-β is considered a key player in AD pathophysiology since dysregulation of this kinase influences all the major hallmarks of the disease including: tau phosphorylation, amyloid-β production, memory, neurogenesis and synaptic function. The present review summarizes the current understanding of the GSK3-β neurobiology with particular emphasis on its effects on specific signaling pathways associated with AD pathophysiology. Moreover, it discusses the feasibility of targeting GSK3-β for AD treatment and provides a summary of the current research effort to develop GSK3-β inhibitors in preclinical and clinical studies.

What this study adds

Evidence grade: Low

This is a narrative review. This review describes the GSK3-β signaling pathway as involved in tau phosphorylation, amyloid-β production, memory, neurogenesis and synaptic function, and discusses it as a possible drug target. It reports that there is currently no cure and that GSK3-β inhibitors are still being studied in preclinical and clinical research.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Lauretti, E., Dincer, O., & Praticò, D. (2020). Glycogen synthase kinase-3 signaling in Alzheimer's disease. Biochimica et biophysica acta. Molecular cell research. https://doi.org/10.1016/j.bbamcr.2020.118664

Vancouver

Lauretti E, Dincer O, Praticò D. Glycogen synthase kinase-3 signaling in Alzheimer's disease. Biochimica et biophysica acta. Molecular cell research. 2020. doi:10.1016/j.bbamcr.2020.118664. PMID: 32006534.

BibTeX

@article{lauretti2020-32006534,
  author  = {Lauretti, E. and Dincer, O. and Praticò, D.},
  title   = {{Glycogen synthase kinase-3 signaling in Alzheimer's disease}},
  journal = {Biochimica et biophysica acta. Molecular cell research},
  year    = {2020},
  doi     = {10.1016/j.bbamcr.2020.118664},
  pmid    = {32006534},
  url     = {https://doi.org/10.1016/j.bbamcr.2020.118664}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This review describes the GSK3-β signaling pathway as involved in tau phosphorylation, amyloid-β production, memory, neurogenesis and synaptic function, and discusses it as a possible drug target. It reports that there is currently no cure and that GSK3-β inhibitors are still being studied in preclinical and clinical research.

Study details

How this study scored 51/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 6 of 7; Citations per year 5 of 5; Impact for its field and year 5 of 6; Cited by studies here 3 of 6; Still being cited 4 of 4; Senior author's track record 3 of 4; Institution's track record 1 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 51 of 100.51 of 100 points earned49 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Biochimica et biophysica acta. Molecular cell research)
Journal's citation record 2 / 4 Biochimica et Biophysica Acta (BBA) - Molecular Cell Research: journal h-index 248 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2020 — within 10 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 6 / 7 Cited 614 times (OpenAlex, 2026-10-10)
Citations per year 5 / 5 76.8 citations a year over 8 year(s) since 2020
Impact for its field and year 5 / 6 Cited 30.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 10 other studies in this library
Still being cited 4 / 4 Cited 376 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Domenico Praticò: h-index 92 (OpenAlex, whole career)
Institution's track record 1 / 3 Temple University: institution h-index 742 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 32006534)
Free to read 0 / 2 Behind a paywall — scores zero
Total 51 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

10 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Caregiving from nearby years

Also tagged “precursor”

1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Caregiving

See all studies in Caregiving →